SEEL - Seelos Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Currency in USD

Valuation Measures

Premium required to access annual data
Annual
Quarterly
Premium required to access monthly data
Monthly
Subscribe to Premium to download historical data
 
As of Date: 7/8/2020
Current
3/31/202012/31/20199/30/20196/30/2019
Market Cap (intraday) 5
45.85M21.58M36.22M24.74M46.60M
Enterprise Value 3
33.16M11.32M20.90M15.01M35.31M
Trailing P/E
0.77N/AN/AN/AN/A
Forward P/E 1
N/AN/AN/AN/AN/A
PEG Ratio (5 yr expected) 1
N/AN/AN/AN/AN/A
Price/Sales (ttm)
72.3726.56N/AN/AN/A
Price/Book (mrq)
6.78N/A3.505.0115.34
Enterprise Value/Revenue 3
88.43N/A55.74N/AN/A
Enterprise Value/EBITDA 6
-1.64-2.35-2.03-4.66-19.06

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-51.72%
S&P500 52-Week Change 35.67%
52 Week High 32.2500
52 Week Low 30.4200
50-Day Moving Average 31.1744
200-Day Moving Average 30.9418

Share Statistics

Avg Vol (3 month) 31.61M
Avg Vol (10 day) 3887.94k
Shares Outstanding 544.95M
Float 37.93M
% Held by Insiders 116.24%
% Held by Institutions 18.33%
Shares Short (Jun 14, 2020) 4668.99k
Short Ratio (Jun 14, 2020) 40.34
Short % of Float (Jun 14, 2020) 41.60%
Short % of Shares Outstanding (Jun 14, 2020) 41.49%
Shares Short (prior month May 14, 2020) 4604.05k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:30
Last Split Date 3Jan 23, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2019
Most Recent Quarter (mrq)Mar 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-6,697.07%

Management Effectiveness

Return on Assets (ttm)-118.39%
Return on Equity (ttm)-419.81%

Income Statement

Revenue (ttm)375k
Revenue Per Share (ttm)0.01
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)375k
EBITDA N/A
Net Income Avi to Common (ttm)-20.57M
Diluted EPS (ttm)-0.7730
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)12.69M
Total Cash Per Share (mrq)0.28
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.97
Book Value Per Share (mrq)0.15

Cash Flow Statement

Operating Cash Flow (ttm)-17.79M
Levered Free Cash Flow (ttm)-17.53M